FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2781248685> ?p ?o ?g. }

• W2781248685 abstract "The taxanes paclitaxel and docetaxel have a low oral bioavailability, as a result of poor water solubility and high first-pass effect. The water-solubility could be improved by the development of solid dispersion formulations for oral use. In this thesis it is shown that the combination of the solid dispersion and inhibitors of CYP3A4 and/or P-gp (e.g. ritonavir) the oral bioavailability of both paclitaxel and docetaxel can be increased. The combination of oral docetaxel (as ModraDoc001 capsule or ModraDoc006 tablet) with ritonavir resulted in clinically relevant exposure at the maximum tolerable dose, which was comparable to a weekly iv docetaxel dose of 35 mg/m2. Partial response was the best response to treatment. Toxicity was manageable with dose-interruptions and dose-reductions. Most common (dose-limiting) toxicities were diarrhea, nausea, vomiting and fatigue. The results are considered promising, further development of oral docetaxel in combination ritonavir is therefore persued in phase II studies. The preliminary design of one of those phase II studies is also described in the thesis. Oral paclitaxel (as ModraPac001 capsule or ModraPac005 tablet) administration in a metronomic schedule in combination with ritonavir was found feasible and safe in a phase I dose-escalation trial. Antitumor activity was thus far limited with stable disease as best response to treatment. Further development will therefore likely focus on combination treatment with other anticancer agents. The novel HDM-p53 interaction inhibitor SAR405838 was investigated in monotherapy and in combination with the MEK inhibitor pimasertib. Anti-tumor efficacy in monotherapy was limited to prolonged stable disease. It was however safe with thrombocytopenia, as the only dose-limiting toxicity. In the combination with pimasertib the antitumor activity was promising with a partial response and prolonged stable disease (>6 months) in seven patients. The toxicity associated with the combination, however led to premature discontinuation of the study. Dose-limiting toxicities were thrombocytopenia, lipase increase and inability to continue treatment as a result of grade 1-2 toxicity. Further studies are needed to ultimately assess the usefulness of this class of anticancer agents in clinical practice." @default.
• W2781248685 created "2018-01-05" @default.
• W2781248685 creator A5006165743 @default.
• W2781248685 date "2017-12-20" @default.
• W2781248685 modified "2023-09-24" @default.
• W2781248685 title "Clinical pharmacology of novel anticancer agents : Focus on oral formulations" @default.
• W2781248685 cites W1531776990 @default.
• W2781248685 cites W1554671812 @default.
• W2781248685 cites W1838206777 @default.
• W2781248685 cites W1861357909 @default.
• W2781248685 cites W1893424794 @default.
• W2781248685 cites W1975565006 @default.
• W2781248685 cites W1993980146 @default.
• W2781248685 cites W2005909074 @default.
• W2781248685 cites W2025533780 @default.
• W2781248685 cites W2057660831 @default.
• W2781248685 cites W2065519386 @default.
• W2781248685 cites W2068633458 @default.
• W2781248685 cites W2076023979 @default.
• W2781248685 cites W2122181353 @default.
• W2781248685 cites W2127385754 @default.
• W2781248685 cites W2136643719 @default.
• W2781248685 cites W2144772995 @default.
• W2781248685 cites W2160766792 @default.
• W2781248685 cites W2165126891 @default.
• W2781248685 cites W2166589211 @default.
• W2781248685 cites W2226282764 @default.
• W2781248685 cites W2256020981 @default.
• W2781248685 cites W2314956816 @default.
• W2781248685 cites W2336906086 @default.
• W2781248685 cites W2560489757 @default.
• W2781248685 cites W2560597540 @default.
• W2781248685 cites W2596468903 @default.
• W2781248685 cites W2596999207 @default.
• W2781248685 cites W2730981009 @default.
• W2781248685 cites W2731663112 @default.
• W2781248685 cites W2755839425 @default.
• W2781248685 hasPublicationYear "2017" @default.
• W2781248685 type Work @default.
• W2781248685 sameAs 2781248685 @default.
• W2781248685 citedByCount "0" @default.
• W2781248685 crossrefType "dissertation" @default.
• W2781248685 hasAuthorship W2781248685A5006165743 @default.
• W2781248685 hasConcept C112705442 @default.
• W2781248685 hasConcept C126322002 @default.
• W2781248685 hasConcept C142462285 @default.
• W2781248685 hasConcept C181389837 @default.
• W2781248685 hasConcept C203014093 @default.
• W2781248685 hasConcept C2776694085 @default.
• W2781248685 hasConcept C2777056448 @default.
• W2781248685 hasConcept C2777292972 @default.
• W2781248685 hasConcept C2778778583 @default.
• W2781248685 hasConcept C2779298103 @default.
• W2781248685 hasConcept C2780580376 @default.
• W2781248685 hasConcept C2780852908 @default.
• W2781248685 hasConcept C2781190966 @default.
• W2781248685 hasConcept C2993143319 @default.
• W2781248685 hasConcept C3013748606 @default.
• W2781248685 hasConcept C59822182 @default.
• W2781248685 hasConcept C71924100 @default.
• W2781248685 hasConcept C86803240 @default.
• W2781248685 hasConcept C98274493 @default.
• W2781248685 hasConceptScore W2781248685C112705442 @default.
• W2781248685 hasConceptScore W2781248685C126322002 @default.
• W2781248685 hasConceptScore W2781248685C142462285 @default.
• W2781248685 hasConceptScore W2781248685C181389837 @default.
• W2781248685 hasConceptScore W2781248685C203014093 @default.
• W2781248685 hasConceptScore W2781248685C2776694085 @default.
• W2781248685 hasConceptScore W2781248685C2777056448 @default.
• W2781248685 hasConceptScore W2781248685C2777292972 @default.
• W2781248685 hasConceptScore W2781248685C2778778583 @default.
• W2781248685 hasConceptScore W2781248685C2779298103 @default.
• W2781248685 hasConceptScore W2781248685C2780580376 @default.
• W2781248685 hasConceptScore W2781248685C2780852908 @default.
• W2781248685 hasConceptScore W2781248685C2781190966 @default.
• W2781248685 hasConceptScore W2781248685C2993143319 @default.
• W2781248685 hasConceptScore W2781248685C3013748606 @default.
• W2781248685 hasConceptScore W2781248685C59822182 @default.
• W2781248685 hasConceptScore W2781248685C71924100 @default.
• W2781248685 hasConceptScore W2781248685C86803240 @default.
• W2781248685 hasConceptScore W2781248685C98274493 @default.
• W2781248685 hasLocation W27812486851 @default.
• W2781248685 hasOpenAccess W2781248685 @default.
• W2781248685 hasPrimaryLocation W27812486851 @default.
• W2781248685 hasRelatedWork W112210410 @default.
• W2781248685 hasRelatedWork W1511489281 @default.
• W2781248685 hasRelatedWork W1603418727 @default.
• W2781248685 hasRelatedWork W1976794537 @default.
• W2781248685 hasRelatedWork W2019200453 @default.
• W2781248685 hasRelatedWork W2129784156 @default.
• W2781248685 hasRelatedWork W2137448351 @default.
• W2781248685 hasRelatedWork W2145687358 @default.
• W2781248685 hasRelatedWork W2285360353 @default.
• W2781248685 hasRelatedWork W2415292021 @default.
• W2781248685 hasRelatedWork W2444491976 @default.
• W2781248685 hasRelatedWork W2496259455 @default.
• W2781248685 hasRelatedWork W2576972117 @default.
• W2781248685 hasRelatedWork W2592529010 @default.
• W2781248685 hasRelatedWork W2617603332 @default.
• W2781248685 hasRelatedWork W26253050 @default.

• next